ATS 2018 International Conference - Mobile

Revefenacin, a Once-Daily, Long-Acting Muscarinic Antagonist for Nebulized Therapy of Chronic Obstructive Pulmonary Disease (COPD): Results of a 52-Week Safety and Tolerability Phase 3 Trial in Participants with Moderate to Very Severe COPD [Board No. 613]

Location: Board no. 613

Session Type: RAPiD: Rapid Abstract Poster Discussion Session

Monday

May

21

2:15 PM

4:15 PM

Speaker(s)/Author(s)

Lorna Dean

MPA
Theravance Biopharma US, Inc

Chris N. Barnes

PhD
Theravance Biopharma US, Inc

Edward M. Kerwin

phd
Clinical Research Institute;Clinical Research Institute of Southern Oregon, PC;Crisor, LLC c/o Clinical Research Institute of Southern Oregon, Inc.

Glenn D. Crater

MD
Theravance Biopharma US, Inc

Edmund J. Moran

PhD
Theravance Biopharma US, Inc

Sanjay Sethi

md
Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo;State University of New York at Buffalo;University at Buffalo;University at Buffalo, State University of New

Brett Haumann

MD, MBA
Theravance Biopharma UK, Limited

James F. Donohue

MD
Univ of N Carolina At Chapel Hill;University of North Carolina

Srikanth Pendyala

MD
Theravance Biopharma US, Inc

View Abstract

Revefenacin, a Once-Daily, Long-Acting Muscarinic Antagonist for Nebulized Therapy of Chronic Obstructive Pulmonary Disease (COPD): Results of a 52-Week Safety and Tolerability Phase 3 Trial in Participants with Moderate to Very Severe COPD

Parent Sessions

B102 - CLINICAL TRIALS AND STUDIES IN COPD...
05-21-2018 2:15 PM - 4:15 PM